The board is smart when it comes to building value in the company. By continuing Covid, Nash, Hiv, and especially cancer trials, each one continues to add value. Some low revenue biotechs have sold from anywhere from $20 billion to $39 billion. CYDY can be higher with more time and continued success with their wonder drug.
Be patient as in biotech terms your payday isn't far away.
Market Data 
Markets 
AI
